Terms: = Prostate cancer AND ENO2, HEL-S-279, NSE
148 results:
1. Limited prognostic role of routine serum markers (AP, CEA, LDH and nse) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.
Mehring G; Steinbach C; Pose R; Knipper S; Koehler D; Werner S; Riethdorf S; von Amsberg G; Ambrosini F; Maurer T
World J Urol; 2024 Apr; 42(1):256. PubMed ID: 38656636
[TBL] [Abstract] [Full Text] [Related]
2. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract] [Full Text] [Related]
3. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
4. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
5. Tumor protein D52 (isoform 3) induces NF-κB - STAT3 mediated EMT driving neuroendocrine differentiation of prostate cancer cells.
Sruthi KK; Natani S; Ummanni R
Int J Biochem Cell Biol; 2024 Jan; 166():106493. PubMed ID: 37935328
[TBL] [Abstract] [Full Text] [Related]
6. Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient.
Valentine H; Aiken W; Morrison B; Zhao Z; Fowle H; Wasserman JS; Thompson E; Chin W; Young M; Clarke S; Gibbs D; Harrison S; McLaughlin W; Kwok T; Jin F; Campbell KS; Horvath A; Thompson R; Lee NH; Zhou Y; Graña X; Ragin C; Badal S
Cancer Res Commun; 2022 Nov; 2(11):1355-1371. PubMed ID: 36643868
[TBL] [Abstract] [Full Text] [Related]
7. Endocrine and paracrine characteristics of neuroendocrine prostate cancer.
Arman T; Nelson PS
Front Endocrinol (Lausanne); 2022; 13():1012005. PubMed ID: 36440195
[TBL] [Abstract] [Full Text] [Related]
8. Recent Progress in Biosensors for Detection of Tumor Biomarkers.
Li M; Jiang F; Xue L; Peng C; Shi Z; Zhang Z; Li J; Pan Y; Wang X; Feng C; Qiao D; Chen Z; Luo Q; Chen X
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364157
[TBL] [Abstract] [Full Text] [Related]
9. Dynamic plasticity of prostate cancer intermediate cells during androgen receptor-targeted therapy.
Sandhu HS; Portman KL; Zhou X; Zhao J; Rialdi A; Sfakianos JP; Guccione E; Kyprianou N; Zhang B; Mulholland DJ
Cell Rep; 2022 Jul; 40(4):111123. PubMed ID: 35905714
[TBL] [Abstract] [Full Text] [Related]
10. Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis.
Kannan A; Clouston D; Frydenberg M; Ilic D; Karim MN; Evans SM; Toivanen R; Risbridger GP; Taylor RA
BJU Int; 2022 Oct; 130(4):420-433. PubMed ID: 34784097
[TBL] [Abstract] [Full Text] [Related]
11. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
[TBL] [Abstract] [Full Text] [Related]
12. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy of radical prostatectomy on prostate cancer patients and analysis of risk factors for biochemical recurrence after radical prostatectomy.
Yang X; Shi Y; Lin Y; Tian Y
J BUON; 2020; 25(6):2623-2628. PubMed ID: 33455105
[TBL] [Abstract] [Full Text] [Related]
14. Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation.
Minagawa H; Kawai T; Matsumoto A; Makino K; Sato Y; Nagasaka K; Tokura M; Tanaka N; Ito E; Yamada Y; Nakamura M; Yamada D; Suzuki M; Murata T; Kume H
BMC Urol; 2021 Jan; 21(1):8. PubMed ID: 33413292
[TBL] [Abstract] [Full Text] [Related]
15. The Combination of CA125 and nse Is Useful for Predicting Liver Metastasis of Lung cancer.
Wang CF; Peng SJ; Liu RQ; Yu YJ; Ge QM; Liang RB; Li QY; Li B; Shao Y
Dis Markers; 2020; 2020():8850873. PubMed ID: 33376560
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant prostate cancer Patients.
Moritz J; Bauernhofer T; Mannweiler S; Langsenlehner T; Pummer K; Dandachi N; Pichler M
In Vivo; 2020; 34(6):3631-3638. PubMed ID: 33144478
[TBL] [Abstract] [Full Text] [Related]
17. The Correlation between PSCA Expression and Neuroendocrine Differentiation in prostate cancer.
Xiang Q; Zhu Z; Luo L; Wang J; Liu Y; Deng Y; Zhou M; Zhao Z
Biomed Res Int; 2020; 2020():5395312. PubMed ID: 33029516
[TBL] [Abstract] [Full Text] [Related]
18. Molecular analysis of circulating tumor cells of metastatic castration-resistant prostate cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
19. Androgen Deprivation Induces Reprogramming of prostate cancer Cells to Stem-Like Cells.
Sánchez BG; Bort A; Vara-Ciruelos D; Díaz-Laviada I
Cells; 2020 Jun; 9(6):. PubMed ID: 32531951
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract] [Full Text] [Related]
[Next]
